title: Significant rate of hepatitis B reactivation following kidney transplantation in patients with resolved infection.
abstract: BACKGROUND
  Limited data is available on the risk of hepatitis B virus (HBV) reactivation in patients with resolved infection undergoing kidney transplantation. It is generally thought that this risk is negligible.
  
  
  OBJECTIVE
  To evaluate the incidence of HBV reactivation in such patients, and the potential risk factors for reactivation.
  
  
  METHODS
  Retrospective cohort study including 93 patients transplanted with a kidney between 1995 and 2007 who had evidence of resolved HBV infection (HBsAg negative, anti-HBc positive, anti-HBs positive or negative, and normal liver enzymes). HBV reactivation was defined as HBsAg reversion with HBV DNA>2000 IU/mL.
  
  
  RESULTS
  Six patients experienced HBsAg reversion followed by HBV reactivation, 3 within the first post-transplant year. Immunosuppression regimen was similar in patients with and without reactivation. Among patients with reactivation only one was positive for anti-HBs antibodies at time of transplantation; these were progressively lost before reactivation. The odds ratio for reactivation in patients without anti-HBs antibodies at transplantation compared to those with anti-HBs antibodies was 26 (95% CI [2.8-240.5], p=0.0012). In patients with anti-HBs antibody titer above 100 IU/L, no reactivation was observed.
  
  
  CONCLUSIONS
  Reactivation rate of resolved hepatitis B is not negligible in patients without anti-HBs antibodies at transplantation. We suggest monitoring of liver tests and HBV serology including HBsAg and anti-HBs antibodies after transplantation as well as vaccination pre- and post-transplantation in all patients, including those with resolved hepatitis B, aiming at maintaining anti-HBs antibody level above 100 IU/L.
authors.affiliation: Division of Nephrology, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain, Brussels, Belgium. nada.kanaan@uclouvain.be
authors.forename: Nada
authors.initials: N
authors.lastname: Kanaan
authors.forename: Benoit
authors.initials: B
authors.lastname: Kabamba
authors.forename: Céline
authors.initials: C
authors.lastname: Maréchal
authors.forename: Yves
authors.initials: Y
authors.lastname: Pirson
authors.forename: Claire
authors.initials: C
authors.lastname: Beguin
authors.forename: Eric
authors.initials: E
authors.lastname: Goffin
authors.forename: Ziad
authors.initials: Z
authors.lastname: Hassoun
mesh_terms: D015331:Cohort Studies; D004279:DNA, Viral / Q000097:blood; D005260:Female; D006509:Hepatitis B / Q000453:epidemiology*; D006514:Hepatitis B Surface Antigens / Q000097:blood; D006515:Hepatitis B virus / Q000472:pathogenicity*; D006801:Humans; D016867:Immunocompromised Host; D015994:Incidence; D016030:Kidney Transplantation; D008297:Male; D008875:Middle Aged; D012189:Retrospective Studies; D014180:Transplantation; D014775:Virus Activation
chemical_list: D004279:DNA, Viral; D006514:Hepatitis B Surface Antigens